You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.
The firm offers a high-throughput, automated and a low-throughput, manual solution and now plans to address mid-range needs with two new instruments.
The firm saw an increase in sales for both the life science and clinical diagnostics segments.
Bio-Rad received 510(k) clearance for its IH-Incubator L and IH-Centrifuge L instruments for use with the company's full range of IH-System Gel Reagents.
The firm has provided glimpses into its strategies for developing a line of regulated droplet digital PCR tests in a number of recent forums.
Among the diagnostic firms presenting at the conference on Tuesday were lab giant LabCorp, diversified medical products firm Hologic, and MDx startups, such as Adaptive Biotechnologies.
The stock prices of 17 of the 25 firms in the 360Dx Index fell month over month with Enzo Biochem and Bio-Rad leading decliners.
The test uses droplet digital PCR to detect BCR-ABL gene fusions and is intended for treatment response monitoring of chronic myeloid leukemia.
Paced by Accelerate Diagnostics and Bio-Rad, the 360Dx Index beat the broader markets. Shares of GenMark and Opko, however, were sharply down.
Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.